Study of Gardasil in Mid-Adult Males (MAM)
NCT01432574
Completed
The purpose of this study is to test the effectiveness of the research study vaccine, Gardasil, in men ages 27-45 who have completed 4 years of observation in The Human Papillomavirus \[HPV\] infection in men (HIM) Study.
Gender:
MALE
Ages:
Between 27 years and 45 years
Trial Updated:
09/13/2021
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida +1 locations
Conditions: Human Papillomavirus
Register for Updates
A Phase 2 Study to Evaluate Immune Responses of FluMist®
NCT00461981
Completed
The primary objective of this study is to describe the level of serum antibody and cellular immune responses conferred by FluMist and TIV against influenza virus strains.
Gender:
ALL
Ages:
Between 12 months and 35 months
Trial Updated:
09/10/2021
Locations: Harvey Pediatrics, Jonesboro, Arkansas +18 locations
Conditions: Influenza Vaccine
Register for Updates
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
NCT03674177
Completed
The purpose of this study is to evaluate different dose levels of the investigational RSV maternal vaccine (GSK3888550A) based on safety/reactogenicity and immune response data. As this is the first time the investigational RSV maternal vaccine (GSK3888550A) is being been used in humans, this study will be performed in healthy non-pregnant women 18-45 years of age before testing in pregnant women.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
08/12/2021
Locations: GSK Investigational Site, Lenexa, Kansas +10 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults
NCT01509846
Completed
This is a research study about an experimental (investigational) oral inactivated whole cell Shigella flexneri 2a killed vaccine (Sf2aWC). Sf2aWC is a killed vaccine that is being made to prevent disease from Shigella., which causes bloody, watery diarrhea. Infants and children living in developing countries experience the greatest consequences of this disease. The purpose of this study is to find a dose of the vaccine that is safe, tolerable, and develops an immune response. About 82 healthy ad... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
08/10/2021
Locations: Center for Immunization Research (CIR) at Johns Hopkins School of Public Health (JHSPH), Baltimore, Maryland +1 locations
Conditions: Shigellosis
Register for Updates
Influenza Immunity in Children
NCT02559505
Completed
This study evaluates how different methods of early exposure to influenza (natural infection, live attenuated influenza vaccination, inactivated influenza vaccination) initially stimulate immunity and poise the immune system to respond to a future challenge with the inactivated influenza vaccine.
Gender:
ALL
Ages:
Between 3 months and 8 years
Trial Updated:
08/05/2021
Locations: University of Rochester, Rochester, New York
Conditions: Influenza
Register for Updates
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
NCT01968083
Completed
Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children. This study will evaluate the safety and immune response to an RSV vaccine in healthy RSV-naïve children.
Gender:
ALL
Ages:
Between 6 months and 24 months
Trial Updated:
07/19/2021
Locations: University of California, UC San Diego CRS, La Jolla, California +4 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
NCT02593227
Completed
This Phase II trial evaluates the safety and immunogenicity of two doses of the Folate Receptor Alpha (FRα) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or without a immune priming with cyclophosphamide, as a consolidation therapy after neoadjuvant or adjuvant treatment of patients with Stage IIb-III triple negative breast cancer (TNBC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/15/2021
Locations: Moffitt Cancer Center, Tampa, Florida +10 locations
Conditions: Breast Cancer
Register for Updates
Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children
NCT04444284
Completed
This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as drops in the nose. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 15 and 59 months who are seropositive to RSV.
Gender:
ALL
Ages:
Between 15 months and 59 months
Trial Updated:
06/26/2021
Locations: Meridian Clinical Research, Norfolk, Nebraska +2 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine
NCT04094883
Completed
The purpose of this study is to test whether the group B meningitis vaccine (brand name Bexsero™) induces immune responses against the bacteria that causes gonorrhea. Participants: Approximately 15 Individuals who are 18-25 years of age that are not pregnant, HIV negative, have no history of congenital immunologic disorder, and are not taking immune suppressive medications will be enrolled on this study at a single site, University of North Carolina at Chapel Hill (UNC-CH). Procedures (methods... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
06/24/2021
Locations: University of North Carolina Health Care, Chapel Hill, North Carolina
Conditions: Neisseria Gonorrhoeae Infection
Register for Updates
A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years
NCT04762511
Terminated
The purpose of this first-time-in-human (FTiH) study is to assess the reactogenicity, safety and immunogenicity of four different dose levels of an experimental herpes simplex virus type 2 (HSV-2) vaccine, when administered intramuscularly (IM) on a 0, 2-month schedule to healthy participants aged 18-40 years.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
06/24/2021
Locations: GSK Investigational Site, Lenexa, Kansas +1 locations
Conditions: Herpes Simplex
Register for Updates
PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC
NCT02544880
Completed
The investigators hypothesize that Tadalafil treatment, by lowering Myeloid Derived Suppressor Cells (MDSCs) and regulatory T cells (Tregs), can prime an antitumor immune response and promote a permissive environment that should increase the efficacy of anti-tumor vaccine in a setting of minimal residual disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2021
Locations: University of Miami, Miami, Florida
Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Register for Updates
HPV Centralized R/R RCT #2 - New York State
NCT03294551
Completed
The work done in this trial builds off of the work previously conducted by this same research group in clinicaltrials.gov ID: NCT03057379. Due to some changes in study design, protocol, and cohort of interest, a new registration was warranted. The overarching goal of this study is to evaluate the effectiveness, cost-effectiveness, and sustainability of utilizing statewide immunization information systems (IISs) to conduct centralized reminder recall (R/R) to improve human papillomavirus (HPV) v... Read More
Gender:
ALL
Ages:
Between 11 years and 14 years
Trial Updated:
05/26/2021
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Vaccines
Register for Updates